MASH is metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and injury. The degree of fibrosis changes treatment decisions.
Call before traveling and name the exact service and location. Confirm the appointment, provider, records, tests, and medicine arrangements. A general walk-in visit does not guarantee a prescription, administration, specialist treatment, or a dietitian appointment that day.
MASH is metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and injury. The degree of fibrosis changes treatment decisions. Simple fatty liver on an ultrasound does not prove MASH or eligibility for Rezdiffra or Wegovy’s MASH indication.
Metabolic conditions can contribute to liver fat, inflammation, and scarring. Liver enzymes may be normal despite fibrosis. Weight improvement and laboratory improvement do not prove that scarring has resolved.
Adults with suspected liver fat or fibrosis need assessment of cause, metabolic risk, and severity. The labeled MASH treatments apply to adults with noncirrhotic MASH and F2–F3 fibrosis. Cirrhosis and other liver diseases need distinct care.
Review liver tests, imaging, noninvasive fibrosis assessments, alcohol, viral risks, medicines, and supplements. A clinician may coordinate hepatology and further testing; biopsy is not automatically required for every patient. Discuss nutrition, activity, diabetes and lipid care, and product-specific treatment when appropriate.
Bring liver tests, imaging, elastography or other fibrosis results, biopsy reports if available, and prior GI notes. Include medicines, alcohol history, and documentation requested by the insurer.
Vomiting blood, new confusion or severe abdominal pain needs emergency department care now. Call 911 for confusion, severe breathing difficulty, fainting or unsafe travel. New jaundice or increasing abdominal swelling needs prompt medical assessment. Avoid unreviewed liver-detox supplements. A normal enzyme result is not permission to stop follow-up.
Follow liver and fibrosis assessment, metabolic goals, and medicine safety with the treating team. Rezdiffra and Wegovy combination decisions need individualized review. The trials and labels do not establish that a combination is appropriate for everyone.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Nao Medical Hicksville: 232 W Old Country Rd, Hicksville, NY 11801. Call +1-917-310-3371 to confirm the specific service, clinician and appointment before travelling.
Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.
Confirm the current address, hours, and appointment arrangements with Nao Medical before traveling. Mention the specific location and mash is metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and injury. Ask whether records, tests, prescription review, training, or administration must be arranged ahead of time.
Call before traveling to confirm the exact service and appointment. An evaluation may require records, tests, or a later treatment decision. A general walk-in appointment does not guarantee medication, an injection, or specialist care that day. Bring liver tests, imaging, elastography or other fibrosis results, biopsy reports if available, and prior GI notes. Include medicines, alcohol history, and documentation requested by the insurer.
Bring liver tests, imaging, elastography or other fibrosis results, biopsy reports if available, and prior GI notes. Include medicines, alcohol history, and documentation requested by the insurer.
No. Liver fat on imaging does not by itself establish noncirrhotic MASH with F2–F3 fibrosis. The clinician reviews diagnosis, severity, and other causes before deciding whether Rezdiffra or Wegovy injection’s MASH indication fits.
No. The Wegovy MASH indication belongs to the injection. Wegovy tablets have adult weight and qualifying cardiovascular indications, not the injection’s MASH indication. Product choice must follow the exact formulation’s label.
A clinician must review the liver diagnosis, fibrosis stage, metabolic needs, side effects, and interactions before combining Rezdiffra with a GLP-1 medicine. The labels do not establish that every patient should use the combination. Keep specialist follow-up and do not add or switch treatments yourself.
If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact Sharad Suri at service@naomedical.com or by phone at (917) 633-1548 Extension 288. In our goal to answer your questions as quick as possible, we use the assistance of a large language model wherever applicable. If there are any errors or concerns, please bring it to our attention by emailing us.
Enter your phone number to begin scheduling your appointment.
You will be redirected to complete the appointment booking. Next: Book Appointment
Nao Medical will never sell your information to a third party.
Choose urgent care for a non-emergency illness or minor injury. For preventive visits and ongoing management, explore primary care at this location.
Visiting later? Review after-hours options and confirm clinic hours before traveling. For a life-threatening emergency, call 911.
(917) 310-3371
Facebook
Instagram
Twitter
LinkedIn
